<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134523</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-006</org_study_id>
    <nct_id>NCT01134523</nct_id>
  </id_info>
  <brief_title>Regimens Comparison for Breast Cancers of Positive Lymph Nodes</brief_title>
  <official_title>Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast
      cancer patients with positive lymph nodes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle *4cycle.
      followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle.

      ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years after all the recuiment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years after all the adjuvent treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>5 years after all the recruiment</time_frame>
    <description>Assessing for Hematology and Non-hematology toxicities, including all SAEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: EC-T regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: ET regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, CTX, Paclitaxel</intervention_name>
    <description>Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.</description>
    <arm_group_label>Group A: EC-T regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Paclitaxel</intervention_name>
    <description>Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.</description>
    <arm_group_label>Group B: ET regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with breast cancer after breast cancer surgery with positive lymph nodes age
             18-70 years old

        Exclusion Criteria:

          -  with other malignance disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan, M.D.</last_name>
    <phone>86-10-8778 8114</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute &amp; Hospital. Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Yuan, M.D.</last_name>
      <phone>86-10-8778 8114</phone>
      <email>yuanpeng01@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Binghe Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Yuan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20458045</url>
    <description>http://www.ncbi.nlm.nih.gov/pubmed/20458045</description>
  </link>
  <reference>
    <citation>Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010 Jun 10;28(17):2874-80. doi: 10.1200/JCO.2009.24.7643. Epub 2010 May 10.</citation>
    <PMID>20458045</PMID>
  </reference>
  <reference>
    <citation>Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide... Moebus et al. J Clin Oncol.2010; 0: JCO.2009.24.7643v1-JCO.2009.24.7643</citation>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>positive lymph node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

